Staidson and Pivotal Collaborate in Trial of Progressive Severe COVID-19 Patients


Applied Clinical Trials

Staidson and Pivotal have announced a new strategic collaboration to assess Staidson´s investigational product BDB-001 in a Europe-based clinical trial in progressive severe COVID-19 patients caused by SARS-CoV-2. This clinical trial is a multicenter, open-label, randomized and controlled study. Sixty patients will be enrolled in the trial, half of them will be administered the drug and the other half will follow the standard of care used at the corresponding center. 

For more information, click here.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.